Innovation & Leadership in Engineering Technologies and Therapies for Diabetes

创新

• 批准号: 8444059
• 负责人: ATHANASSIOS SAMBANIS
• 金额: $ 16.91万
• 依托单位: GEORGIA INSTITUTE OF TECHNOLOGY
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-17 至 2014-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8444059
• 关键词: Academia; Affect; Area; Artificial Pancreas; Autologous; Beta Cell; Biocompatible Materials; Biological; Biomedical Engineering; Biotechnology; Caring; Cell Therapy; Cells; Clinical; Complex; Development; Diabetes Mellitus; Economic Burden; Encapsulated; Engineering; Engraftment; Exposure to; Generations; Glucose; Health; Health Care Costs; Hydrogels; Immune; Industry; Injection of therapeutic agent; Institutes; Insulin; Insulin Infusion Systems; Insulin-Dependent Diabetes Mellitus; Joints; Leadership; Life; Methods; Microfabrication; Pancreas; Patient Care; Patients; Physiological; Population; Positioning Attribute; Process; Protocols documentation; Quality of life; Research; Research Training; Sampling; Science; System; Technology; Tissues; Training; Training Programs; Transplantation; Universities; base; beta cell replacement; blood glucose regulation; commercialization; diabetes management; diabetes mellitus therapy; diabetic; improved; innovation; islet; islet allograft; islet xenograft; medical schools; next generation; non-invasive monitor; novel; post-doctoral training; programs; translational medicine

DESCRIPTION (provided by applicant): The Diabetes Program: Innovation & Leadership in Engineering Technologies and Therapies (ILET2) is a unique, cross-disciplinary postdoctoral training program in cell- and tissue-based therapies and novel insulin delivery technologies for insulin-dependent diabetes (IDD). IDD is a significant health problem affecting millions of people in the U.S and worldwide. Compared to current treatments based on insulin injections or open-loop insulin pumps, new generation therapies have the potential to provide a less invasive, more physiologic and ultimately less costly regulation of blood glucose levels, potentially reducing long-term complications and revolutionizing diabetes care. There is a critical need for cross-disciplinary training of bioengineers and bioscientists in the complex problems relating to developing living biological substitutes for beta cell replacement and the artificial pancreas, which encompass fundamental science, bioengineering and translational medicine. ILET2 is a joint training program between the Georgia Institute of Technology and Emory University School of Medicine. This program will train the future research experts in this field by providing trainee with expertise in the following areas critical to advancing the next generation therapies for diabetes: 1) the ability to develop new islet encapsulation and engraftment systems, including new biomaterials and processes; 2) the ability to engineer immune acceptance of islet allografts and xenografts; 3) the ability to engineer non-beta insulin- secreting, physiologically responsive cells as an alternative to islets; and 4) the ability to develop new methods for glucose sampling and insulin delivery towards a closed loop artificial pancreas system. Research-based training in cell-based therapies will specialize in encapsulated systems for islets and other insulin-secreting cells; the engineering of potentially autologous beta cell surrogates; the development of vasculogenic hydrogels for improved islet engraftment; methods to conduct non-invasive monitoring of islet transplants; and development of immune acceptance protocols for free and encapsulated islet allografts and xenografts. Training specific to insulin delivery methods will focus on the engineering of microneedle technologies for glucose sampling and delivery of insulin, including microfabrication and biomaterials, ultimately as part of a closed loop artificia pancreas system. The research training program will encompass exposure to the clinical aspects of diabetes management and patient care, as well as the industrial aspects of biotechnology development and commercialization. Upon successful completion of the program, trainees will be prepared to move into leadership positions in industry and academia and develop new, cutting-edge technologies and therapies for diabetics aimed at improving the quality of life of patients and reducing the economic burden on the diabetic population and the overall healthcare costs. PUBLIC HEALTH RELEVANCE: Diabetes is a significant health problem affecting approximately 23.6 million people in the US; furthermore, it is estimated that the diabetics who receive insulin either by itself or in combination with oral medication are 27% of the total population of diabetics, or roughly 6.4 million people in the US. New generation therapies comprised of living pancreatic substitutes or closed-loop artificial pancreas systems have the potential to provide a less invasive, more physiologic and ultimately less costly regulation of blood glucose levels than current treatments based on insulin injections or open-loop insulin pumps. This application aims to develop a comprehensive, cross-disciplinary research and education program for the in-depth training of post-doctoral fellows in the next generation technologies and therapies for insulin-dependent diabetes.

描述（由申请人提供）：糖尿病计划：工程技术和疗法的创新和领导力（ILET2）是一项独特的，跨学科的博士后培训计划，用于基于细胞和组织的疗法和新颖的胰岛素胰岛素递送技术，用于胰岛素依赖性糖尿病（IDD）。 IDD是一个重大的健康问题，影响了美国和全球数百万人。与基于胰岛素注射或开环胰岛素泵的当前治疗相比，新一代疗法有可能提供较小的侵入性，更加生理的且最终对血糖水平的成本调节，从而减少了长期并发症和革命性的糖尿病护理。在与开发生物生物学替代品有关β细胞替代品和人工胰腺的复杂问题中，对生物工程师和生物科学家的跨学科培训迫切需要，这些问题涵盖了基本的科学，生物工程和翻译医学。 ILET2是佐治亚理工学院与埃默里大学医学院之间的联合培训计划。该计划将通过为受训者提供以下方面的专业知识来培训该领域的未来研究专家，这对于推进下一代糖尿病疗法至关重要：1）开发新的胰岛封装和植入系统的能力，包括新的生物材料和过程； 2）能够设计胰岛和异种移植物免疫接受的能力； 3）能够设计非β胰岛素，生理响应细胞的能力，以替代胰岛； 4）能够开发新方法，用于葡萄糖采样和胰岛素递送到封闭环的人造胰腺系统。基于细胞的疗法的研究培训将专门研究胰岛和其他分泌胰岛素的封装系统 细胞；潜在的自体β细胞代理的工程；用于改善胰岛植入的血管生成水凝胶的发展；对胰岛移植的非侵入性监测的方法；以及开发自由和封装的胰岛同种异体移植物和异种移植物的免疫接受方案。特定于胰岛素递送方法的训练将集中在微针技术的工程上，用于葡萄糖采样和胰岛素的递送，包括微结构和生物材料，最终是封闭环的胰腺胰腺系统的一部分。 该研究培训计划将涵盖暴露于糖尿病管理和患者护理的临床方面，以及生物技术发展和商业化的工业方面。成功完成该计划后，学员将准备进入行业和学术界的领导地位，并开发新的，尖端的技术和糖尿病患者的疗法，旨在改善患者的生活质量并减轻糖尿病人口的经济负担以及整体医疗保健成本。 公共卫生相关性：糖尿病是一个重大的健康问题，影响了美国约2360万人；此外，据估计，接受胰岛素或与口服药物结合使用的糖尿病患者是糖尿病患者总人群的27％，在美国约有640万人。与基于基于胰岛素注射剂或开放环胰岛素胰岛素泵的当前治疗相比，由活胰腺替代品或闭环人造胰腺系统组成的新一代疗法具有潜在的侵入性，更多的生理性和最终成本较低的血糖水平调节。该应用程序旨在开发一项全面的，跨学科的研究和教育计划，以在下一代技术和胰岛素依赖性糖尿病的疗法中对博士后研究员进行深入培训。